Immunotherapy for Breast Cancer: Current and Future Strategies
Author:
Publisher
Springer Science and Business Media LLC
Subject
Surgery
Link
http://link.springer.com/article/10.1007/s40137-017-0194-1/fulltext.html
Reference94 articles.
1. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–8.
2. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–21.
3. •• Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 . This review highlights the normal and aberrant cellular processes that lead to the development of human cancer from initial genetic changes to metastatic potential.
4. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunother Sci. 2013;342(6165):1432–3. doi: 10.1126/science.342.6165.1432 .
5. •• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733. doi: 10.1056/NEJMoa1103849 . This is the initial descripton of the use of CAR-T cells in a clinical application for CLL, and describes the first-of-its-kind immunotherapy to be FDA approved.
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers;Experimental Hematology & Oncology;2024-07-26
2. Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy;Cellular & Molecular Immunology;2024-04-11
3. FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective;Molecular Biotechnology;2024-03-08
4. Simulation and Experimental Study on the Responses of Subcellular Structures in Tumor Cells Induced by 5 ns Pulsed Electric Fields;Applied Sciences;2023-07-13
5. Breast Cancer: Epidemiology, Types, Diagnosis, and Treatment;Genetics and Epigenetics of Breast Cancer;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3